Compared to non-engineered exosomes, these exosomes exhibited better cellular uptake by EGFR- or HER2-expressing breast cancer cells in vitro, showing approximately twofold and two ~ threefold higher accumulation, respectively [108, 110]. This evidence concerns the gene ERBB2 and breast cancer.